References

1. Chitnis MM, Yuen JS, Protheroe AS, et al. The type 1 insulin-like growth factor receptor pathway.Clin Cancer Res 2008,14:6364-6370.
2. Werner H, Bruchim I. The insulin-like growth factor-I receptor as an oncogene.Arch Physiol Biochem 2009, 115:58-71.
3. Davies M, Gupta S, Goldspink G, Winslet M. The insulin-like growth factor system and colorectal cancer: clinical and experimental evidence.Int J Colorectal Dis 2006, 21:201-208.
4. Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer.J Natl Cancer Inst 2002, 94:972-980.
5. Kaaks R. Nutrition, insulin, IGF-1 metabolism and cancer risk: a summary of epidemiological evidence.Novartis Found Symp 2004, 262:247-260; discussion 260-268.
6. Lamberts SW, van den Beld AW, van der Lely AJ. The endocrinology of aging.Science 1997, 278:419-424.
7. Doi T, Shimada H, Makizako H, et al. Association of insulin-like growth factor-1 with mild cognitive impairment and slow gait speed.Neurobiol Aging 2015, 36:942-947.
8. Calvo D, Gunstad J, Miller LA, et al. Higher serum insulin-like growth factor-1 is associated with better cognitive performance in persons with mild cognitive impairment.Psychogeriatrics 2013, 13:170-174.
9. Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors.Endocr Rev 1994,15:80-101.
10. Clemmons DR, Seek MM, Underwood LE. Supplemental essential amino acids augment the somatomedin-C/insulin-like growth factor I response to refeeding after fasting.Metabolism 1985, 34:391-395.
11. Runchey SS, Pollak MN, Valsta LM, et al. Glycemic load effect on fasting and post-prandial serum glucose, insulin, IGF-1 and IGFBP-3 in a randomized, controlled feeding study.Eur J Clin Nutr 2012, 66:1146-1152.
12. Brand-Miller JC, Liu V, Petocz P, Baxter RC. The glycemic index of foods influences postprandial insulin-like growth factor-binding protein responses in lean young subjects.Am J Clin Nutr 2005, 82:350-354.
13. Biddinger SB, Ludwig DS. The insulin-like growth factor axis: a potential link between glycemic index and cancer.Am J Clin Nutr 2005, 82:277-278.
14. Burgers AM, Biermasz NR, Schoones JW, et al. Meta-analysis and dose-response metaregression: circulating insulin-like growth factor I (IGF-I) and mortality.J Clin Endocrinol Metab 2011, 96:2912-2920.
15. Ranke MB, Osterziel KJ, Schweizer R, et al. Reference levels of insulin-like growth factor I in the serum of healthy adults: comparison of four immunoassays.Clin Chem Lab Med 2003, 41:1329-1334.
16. Bidlingmaier M, Friedrich N, Emeny RT, et al. Reference intervals for insulin-like growth factor-1 (igf-i) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations.J Clin Endocrinol Metab 2014, 99:1712-1721.
17. Brabant G, von zur Muhlen A, Wuster C, et al. Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study.Horm Res 2003, 60:53-60.
18. Crowe FL, Key TJ, Allen NE, et al. The association between diet and serum concentrations of IGF-I, IGFBP-1, IGFBP-2, and IGFBP-3 in the European Prospective Investigation into Cancer and Nutrition.Cancer Epidemiol Biomarkers Prev 2009,18:1333-1340.
19. Fontana L, Klein S, Holloszy JO. Long-term low-protein, low-calorie diet and endurance exercise modulate metabolic factors associated with cancer risk.Am J Clin Nutr 2006, 84:1456-1462.
20. Fontana L, Weiss EP, Villareal DT, et al. Long-term effects of calorie or protein restriction on serum IGF-1 and IGFBP-3 concentration in humans.Aging Cell 2008, 7:681-687.
21. Friedrich N, Haring R, Nauck M, et al. Mortality and serum insulin-like growth factor (IGF)-I and IGF binding protein 3 concentrations.J Clin Endocrinol Metab 2009, 94:1732-1739.
22. Carlzon D, Svensson J, Petzold M, et al. Both low and high serum IGF-1 levels associate with increased risk of cardiovascular events in elderly men.J Clin Endocrinol Metab 2014, 99:E2308-2316.
23. Svensson J, Carlzon D, Petzold M, et al. Both low and high serum IGF-I levels associate with cancer mortality in older men.J Clin Endocrinol Metab 2012, 97:4623-4630. .
24. van Bunderen CC, van Nieuwpoort IC, van Schoor NM, et al. The Association of Serum Insulin-Like Growth Factor-I with Mortality, Cardiovascular Disease, and Cancer in the Elderly: A Population-Based Study.J Clin Endocrinol Metab 2010.
25. Arai Y, Takayama M, Gondo Y, et al. Adipose endocrine function, insulin-like growth factor-1 axis, and exceptional survival beyond 100 years of age.J Gerontol A Biol Sci Med Sci 2008, 63:1209-1218.
26. Johnsen SP, Hundborg HH, Sorensen HT, et al. Insulin-like growth factor (IGF) I, -II, and IGF binding protein-3 and risk of ischemic stroke.J Clin Endocrinol Metab 2005, 90:5937-5941.
27. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer.Lancet 1998, 351:1393-1396.
28. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study.Science 1998, 279:563-566.